Search

Your search keyword '"Suter, Lisa G."' showing total 269 results
Start Over Author "Suter, Lisa G."
269 results on '"Suter, Lisa G."'

3. Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process With Rheumatology Informatics System for Effectiveness (RISE) Registry Data Review

Author

Bartels, Christie M., Jorge, April, Feldman, Candace H., Zell, JoAnn, Bermas, Bonnie, Barber, Claire E. H., Duarte‐García, Alí, Garg, Shivani, Haseley, Leah, Jatwani, Shraddha, Johansson, Tracy, Limanni, Alex, Rodgers, Wendy, Rovin, Brad H., Santiago‐Casas, Yesenia, Suter, Lisa G., Barnado, April, Ude, Jennifer, Aguirre, Alfredo, Li, Jing, Schmajuk, Gabriela, and Yazdany, Jinoos

Published
2023
Full Text
View/download PDF

4. Systematic Review and Appraisal of the Cross‐Cultural Validity of Functional Status Assessment Measures in Rheumatoid Arthritis

Author

Kulhawy‐Wibe, Stephanie C, Zell, JoAnn, Michaud, Kaleb, Yazdany, Jinoos, Davis, Aileen M, Ehrlich‐Jones, Linda, Thorne, J Carter, Everix, Donna, Cappelli, Laura C, Suter, Lisa G, Limanni, Alex, and Barber, Claire EH

Subjects
Health Services and Systems, Health Sciences, Arthritis, Clinical Research, Arthritis, Rheumatoid, Culturally Competent Care, Disability Evaluation, Health Status Indicators, Humans, Reproducibility of Results, Clinical Sciences, Public Health and Health Services, Psychology, Clinical sciences, Allied health and rehabilitation science
Abstract

ObjectiveWe conducted a systematic review and appraisal of the cross-cultural adaptation and cross-cultural validity of the Health Assessment Questionnaire (HAQ) and its derivatives, and of the more recent Patient-Reported Outcomes Measurement Information System (PROMIS) functional status assessment measures (FSAMs) in rheumatoid arthritis.MethodsFour electronic medical databases were searched from inception until April 4, 2018 according to the Consensus-Based Standards for the Selection of Health Measurement Instruments (COSMIN) group search strategy. Included studies were evaluated using the COSMIN tool for cross-cultural validity and were scored as excellent, good, fair, or poor.ResultsOf 58 articles identified by our search strategy and 3 by manual search, 39 were included: 29 described the translation, cultural adaptation, or cross-cultural validity of the HAQ disability index, 8 other HAQ derivatives, and 2 PROMIS measures, representing 22 languages. Of the 39 articles reviewed, 3 examined the cross-cultural validity of translated versions. These studies were rated as follows: 2 as excellent, 3 good, 13 fair, and 21 poor. Two studies examining cross-cultural validity noted differential item functioning (DIF) between Dutch and US populations for the HAQ-II and PROMIS measures, and a third study found DIF between Turkish and UK populations on the HAQ, indicating cultural differences in questionnaire response.ConclusionThis review highlights a paucity of data on the cross-cultural validity of FSAMs and the mostly poor- or fair-quality methods by which they were translated and adapted, which needs to be considered when using these measures for multinational clinical trials and for day-to-day use in clinical practice.

Published
2020

6. Pre-COVID-19 hospital quality and hospital response to COVID-19: examining associations between risk-adjusted mortality for patients hospitalised with COVID-19 and pre-COVID-19 hospital quality

Author

Peter, Doris, primary, Li, Shu-Xia, additional, Wang, Yongfei, additional, Zhang, Jing, additional, Grady, Jacqueline, additional, McDowell, Kerry, additional, Norton, Erica, additional, Lin, Zhenqiu, additional, Bernheim, Susannah, additional, Venkatesh, Arjun K, additional, Fleisher, Lee A, additional, Schreiber, Michelle, additional, Suter, Lisa G, additional, and Triche, Elizabeth W, additional

Published
2024
Full Text
View/download PDF

8. American College of Rheumatology White Paper on Performance Outcome Measures in Rheumatology

Author

Suter, Lisa G, Barber, Claire E, Herrin, Jeph, Leong, Amye, Losina, Elena, Miller, Amy, Newman, Eric, Robbins, Mark, Tory, Heather, and Yazdany, Jinoos

Subjects
Health Services, Clinical Research, Autoimmune Disease, Arthritis, 8.4 Research design and methodologies (health services), Health and social care services research, Humans, Outcome Assessment, Health Care, Quality of Health Care, Rheumatic Diseases, Rheumatology, Societies, Medical, United States, Clinical Sciences, Public Health and Health Services, Psychology
Abstract

ObjectiveTo highlight the opportunities and challenges of developing and implementing performance outcome measures in rheumatology for accountability purposes.MethodsWe constructed a hypothetical performance outcome measure to demonstrate the benefits and challenges of designing quality measures that assess patient outcomes. We defined the data source, measure cohort, reporting period, period at risk, measure outcome, outcome attribution, risk adjustment, reliability and validity, and reporting approach. We discussed outcome measure challenges specific to rheumatology and to fields where patients have predominantly chronic, complex, ambulatory care-sensitive conditions.ResultsOur hypothetical outcome measure was a measure of rheumatoid arthritis disease activity intended for evaluating Accountable Care Organization performance. We summarized the components, benefits, challenges, and tradeoffs between feasibility and usability. We highlighted how different measure applications, such as for rapid cycle quality improvement efforts versus pay for performance programs, require different approaches to measure development and testing. We provided a summary table of key take-home points for clinicians and policymakers.ConclusionPerformance outcome measures are coming to rheumatology, and the most effective and meaningful measures can only be created through the close collaboration of patients, providers, measure developers, and policymakers. This study provides an overview of key issues and is intended to stimulate a productive dialogue between patients, practitioners, insurers, and government agencies regarding optimal performance outcome measure development.

Published
2016

11. Lifetime Medical Costs of Knee Osteoarthritis Management in the United States: Impact of Extending Indications for Total Knee Arthroplasty

Author

Losina, Elena, Paltiel, A David, Weinstein, Alexander M, Yelin, Edward, Hunter, David J, Chen, Stephanie P, Klara, Kristina, Suter, Lisa G, Solomon, Daniel H, Burbine, Sara A, Walensky, Rochelle P, and Katz, Jeffrey N

Subjects
Osteoarthritis, Chronic Pain, Health Services, Pain Research, Arthritis, Aging, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Musculoskeletal, Good Health and Well Being, Adult, Aged, Arthroplasty, Replacement, Knee, Female, Health Care Costs, Health Services Needs and Demand, Humans, Male, Middle Aged, Models, Economic, Osteoarthritis, Knee, United States, Clinical Sciences, Public Health and Health Services, Psychology
Abstract

ObjectiveThe impact of increasing utilization of total knee arthroplasty (TKA) on lifetime costs in persons with knee osteoarthritis (OA) is understudied.MethodsWe used the Osteoarthritis Policy Model to estimate total lifetime costs and TKA utilization under a range of TKA eligibility criteria among US persons with symptomatic knee OA. Current TKA utilization was estimated from the Multicenter Osteoarthritis Study and calibrated to Health Care Cost and Utilization Project data. OA treatment efficacy and toxicity were drawn from published literature. Costs in 2013 dollars were derived from Medicare reimbursement schedules and Red Book Online. Time costs were derived from published literature and the US Bureau of Labor Statistics.ResultsEstimated average discounted (3% per year) lifetime costs for persons diagnosed with knee OA were $140,300. Direct medical costs were $129,600, with $12,400 (10%) attributable to knee OA over 28 years. OA patients spent a mean ± SD of 13 ± 10 years waiting for TKA after failing nonsurgical regimens. Under current TKA eligibility criteria, 54% of knee OA patients underwent TKA over their lifetimes. Estimated OA-related discounted lifetime direct medical costs ranged from $12,400 (54% TKA uptake) when TKA eligibility was limited to Kellgren/Lawrence grades 3 or 4 to $16,000 (70% TKA uptake) when eligibility was expanded to include symptomatic OA with a lesser degree of structural damage.ConclusionBecause of low efficacy of nonsurgical regimens, knee OA treatment-attributable costs are low, representing a small portion of all costs for OA patients. Expanding TKA eligibility increases OA-related costs substantially for the population, underscoring the need for more effective nonoperative therapies.

Published
2015

13. Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs

Author

Baker, Hailey, primary, Fine, Rebecca, additional, Suter, Fenn, additional, Allore, Heather, additional, Hsiao, Betty, additional, Chowdhary, Vaidehi, additional, Lavelle, Elizabeth, additional, Chen, Ping, additional, Hintz, Richard, additional, Suter, Lisa G., additional, and Danve, Abhijeet, additional

Published
2023
Full Text
View/download PDF

15. Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process with RISE Registry Data Review

Author

Bartels, Christie M., primary, Jorge, April, additional, Feldman, Candace H., additional, Zell, JoAnn, additional, Bermas, Bonnie, additional, Barber, Claire E.H., additional, Duarte‐García, Alí, additional, Garg, Shivani, additional, Haseley, Leah, additional, Jatwani, Shraddha, additional, Johansson, Tracy, additional, Limanni, Alex, additional, Rodgers, Wendy, additional, Rovin, Brad H., additional, Casas, Yesenia Santiago, additional, Suter, Lisa G., additional, Barnado, April, additional, Ude, Jennifer, additional, Aguirre, Alfredo, additional, Li, Jing, additional, Schmajuk, Gabriela, additional, and Yazdany, Jinoos, additional

Published
2023
Full Text
View/download PDF

18. Cost‐Effectiveness of Surgical Weight‐Loss Interventions for Patients With Knee Osteoarthritis and Class III Obesity

Author

Kostic, Aleksandra M., primary, Leifer, Valia P., additional, Gong, Yusi, additional, Robinson, Malcolm K., additional, Collins, Jamie E., additional, Neogi, Tuhina, additional, Messier, Stephen P., additional, Hunter, David J., additional, Selzer, Faith, additional, Suter, Lisa G., additional, Katz, Jeffrey N., additional, and Losina, Elena, additional

Published
2022
Full Text
View/download PDF

23. National Patterns of Risk-Standardized Mortality and Readmission After Hospitalization for Acute Myocardial Infarction, Heart Failure, and Pneumonia: Update on Publicly Reported Outcomes Measures Based on the 2013 Release

Author

Suter, Lisa G., Li, Shu-Xia, Grady, Jacqueline N., Lin, Zhenqiu, Wang, Yongfei, Bhat, Kanchana R., Turkmani, Dima, Spivack, Steven B., Lindenauer, Peter K., Merrill, Angela R., Drye, Elizabeth E., Krumholz, Harlan M., and Bernheim, Susannah M.

Published
2014
Full Text
View/download PDF

29. Observation 'services' and observation 'care'--one word can mean a world of difference

Author

Venkatesh, Arjun K. and Suter, Lisa G.

Subjects
United States. Centers for Medicare and Medicaid Services -- Health policy, Medicare -- Laws, regulations and rules, Hospitals -- Laws, regulations and rules -- United States, Government regulation, Business, Health care industry
Abstract

Observation care, observation status, and observation stays have recently become the focus of considerable policy, provider, and patient attention. A key component of this public debate has focused on whether [...]

Published
2014
Full Text
View/download PDF

31. Administrative Claims Measure for Profiling Hospital Performance Based on 90-Day All-Cause Mortality Following Coronary Artery Bypass Graft Surgery

Author

Mori, Makoto, primary, Nasir, Khurram, additional, Bao, Haikun, additional, Jimenez, Andreina, additional, Legore, Shani S., additional, Wang, Yongfei, additional, Grady, Jacqueline, additional, Lama, Sonam D, additional, Brandi, Nina, additional, Lin, Zhenqiu, additional, Kurlansky, Paul, additional, Geirsson, Arnar, additional, Bernheim, Susannah M, additional, Krumholz, Harlan M, additional, and Suter, Lisa G., additional

Published
2021
Full Text
View/download PDF

33. Additional file 1 of Timely estimation of National Admission, readmission, and observation-stay rates in medicare patients with acute myocardial infarction, heart failure, or pneumonia using near real-time claims data

Author

Li, Shu-Xia, Yongfei Wang, Sonam D. Lama, Schwartz, Jennifer, Jeph Herrin, Mei, Hao, Zhenqiu Lin, Bernheim, Susannah M., Spivack, Steven, Krumholz, Harlan M., and Suter, Lisa G.

Abstract

Additional file 1: Figure A1. Monthly cohort definition for AMI, HF or Pneumonia Readmissions and Observation Stays (Pg.2). Figure A2. Hierarchy for multiple post-discharge care events (Pg. 2). Table A1. Cumulative numbers and percentages of final action inpatient claims uploaded to the IDR for all conditions with a discharge date in January 2013 and July 2013 (as of December 2014) (Pg.3). Figure A3: Modeling approach (Pg.3). Figure A4. Timing of calculating monthly outcomes (Pg.4). Table A2. Final model specification for prediction of number of admissions, readmission rate, and observation-stay rate in AMI cohort (Pg.4). Table A3: Specifications of the final real-time reporting models for Heart failure and pneumonia (Pg.6). Table A4: Results of look-back validation where we compare the rates estimated (for the months July 2016 through December 2016) in February 2017 using RTR models with the final rates later observed using data downloaded from the IDR in February 2018 for AMI, HF and Pneumonia (Pg.7). Figure A5. Prediction and look-back validation for heart failure admission, readmission and observation stays (July 2016–December 2016) (Pg.8). Figure A6. Prediction and look-back validation for pneumonia admission, readmission and observation stays (July 2016–December 2016 (Pg.9).

Published
2020
Full Text
View/download PDF

42. An instrument for assessing the quality of informed consent documents for elective procedures: development and testing

Author

Spatz, Erica S, primary, Suter, Lisa G, additional, George, Elizabeth, additional, Perez, Mallory, additional, Curry, Leslie, additional, Desai, Vrunda, additional, Bao, Haikun, additional, Geary, Lori L, additional, Herrin, Jeph, additional, Lin, Zhenqiu, additional, Bernheim, Susannah M, additional, and Krumholz, Harlan M, additional

Published
2020
Full Text
View/download PDF

45. Reply

Author

England, Bryant R., primary, Mikuls, Ted R., additional, O'Dell, James R., additional, Tiong, Benedict K., additional, Ranganath, Veena K., additional, Bergman, Martin J., additional, Curtis, Jeffrey R., additional, Kazi, Salahuddin, additional, Limanni, Alex, additional, Suter, Lisa G., additional, and Michaud, Kaleb, additional

Published
2020
Full Text
View/download PDF

50. Cost-Effectiveness of Diet and Exercise for Overweight and Obese Knee Osteoarthritis Patients

Author

Losina, Elena, Smith, Karen C., Paltiel, A. David, Collins, Jamie E., Suter, Lisa G., Hunter, David J., Katz, Jeffrey N., and Messier, Stephen P.

Subjects
Male, Comparative Effectiveness Research, Time Factors, Cost-Benefit Analysis, Health Care Costs, Middle Aged, Osteoarthritis, Knee, Article, Models, Economic, Treatment Outcome, Weight Loss, Quality of Life, Humans, Computer Simulation, Female, Healthy Lifestyle, Obesity, Quality-Adjusted Life Years, Exercise, Monte Carlo Method, Risk Reduction Behavior, health care economics and organizations, Aged, Caloric Restriction
Abstract

The Intensive Diet and Exercise for Arthritis (IDEA) trial showed that an intensive diet and exercise (D+E) program led to a mean 10.6-kg weight reduction and 51% pain reduction in patients with knee osteoarthritis (OA). The aim of the current study was to investigate the cost-effectiveness of adding this D+E program to treatment in overweight and obese (body mass index27 kg/mWe used the Osteoarthritis Policy Model to estimate quality-adjusted life-years (QALYs) and lifetime costs for overweight and obese patients with knee OA, with and without the D+E program. We evaluated cost-effectiveness with the incremental cost-effectiveness ratio (ICER), a ratio of the differences in lifetime cost and QALYs between treatment strategies. We considered 3 cost-effectiveness thresholds: $50,000/QALY, $100,000/QALY, and $200,000/QALY. Analyses were conducted from health care sector and societal perspectives and used a lifetime horizon. Costs and QALYs were discounted at 3% per year. D+E characteristics were derived from the IDEA trial. Deterministic and probabilistic sensitivity analyses (PSAs) were used to evaluate parameter uncertainty and the effect of extending the duration of the D+E program.In the base case, D+E led to 0.054 QALYs gained per person and cost $1,845 from the health care sector perspective and $1,624 from the societal perspective. This resulted in ICERs of $34,100/QALY and $30,000/QALY. In the health care sector perspective PSA, D+E had 58% and 100% likelihoods of being cost-effective with thresholds of $50,000/QALY and $100,000/QALY, respectively.Adding D+E to usual care for overweight and obese patients with knee OA is cost-effective and should be implemented in clinical practice.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results